Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.

Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, Radcliffe L, Suhler E, Choi D, Herrinton LJ.

Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):229-35. doi: 10.1002/pds.2049. Epub 2010 Dec 10.

2.

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ.

Ann Rheum Dis. 2013 Jan;72(1):37-42. doi: 10.1136/annrheumdis-2011-200690. Epub 2012 Apr 20.

PMID:
22523429
3.

A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.

Chung CP, Rohan P, Krishnaswami S, McPheeters ML.

Vaccine. 2013 Dec 30;31 Suppl 10:K41-61. doi: 10.1016/j.vaccine.2013.03.075. Review.

PMID:
24331074
4.

Increased risk of mycobacterial infections associated with anti-rheumatic medications.

Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, Li P, Marchand-Austin A, Bombardier C, Marras TK.

Thorax. 2015 Jul;70(7):677-82. doi: 10.1136/thoraxjnl-2014-206470. Epub 2015 Apr 24.

PMID:
25911222
5.

Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.

Yoo JW, Jo KW, Kang BH, Kim MY, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Shim TS.

Eur Respir J. 2014 Nov;44(5):1289-95. doi: 10.1183/09031936.00063514. Epub 2014 Aug 7.

6.

Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.

Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA.

Lung. 2013 Oct;191(5):565-71. doi: 10.1007/s00408-013-9481-5. Epub 2013 Jun 1.

PMID:
23728990
7.

[Biologics and mycobacterial diseases].

Tsuyuguchi K, Matsumoto T.

Kekkaku. 2013 Mar;88(3):337-53. Japanese.

PMID:
23672175
8.

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA.

Emerg Infect Dis. 2009 Oct;15(10):1556-61. doi: 10.3201/eid1510.090310. Review.

9.

Clinical investigation of nontuberculous mycobacterial lung disease in Japanese patients with rheumatoid arthritis receiving biologic therapy.

Yamakawa H, Takayanagi N, Ishiguro T, Kanauchi T, Hoshi T, Sugita Y.

J Rheumatol. 2013 Dec;40(12):1994-2000. doi: 10.3899/jrheum.130511. Epub 2013 Nov 1.

PMID:
24187100
10.

Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease.

Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K.

Am J Respir Crit Care Med. 2010 Oct 1;182(7):977-82. doi: 10.1164/rccm.201003-0503OC. Epub 2010 May 27.

PMID:
20508209
11.

Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis.

Shu CC, Wang JT, Wang JY, Yu CJ, Lee LN; TAMI group.

Clin Microbiol Infect. 2012 Mar;18(3):246-52. doi: 10.1111/j.1469-0691.2011.03547.x. Epub 2011 Jun 1.

12.

Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada.

Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, Li P, Marchand-Austin A, Bombardier C, Marras TK.

Chest. 2014 Sep;146(3):563-72. doi: 10.1378/chest.13-2058.

PMID:
24384637
13.

Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology.

Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL.

Clin Infect Dis. 2009 Dec 15;49(12):e124-9. doi: 10.1086/648443.

14.

Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003.

Marras TK, Chedore P, Ying AM, Jamieson F.

Thorax. 2007 Aug;62(8):661-6. Epub 2007 Feb 20.

16.

Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.

Mori S, Tokuda H, Sakai F, Johkoh T, Mimori A, Nishimoto N, Tasaka S, Hatta K, Matsushima H, Kaise S, Kaneko A, Makino S, Minota S, Yamada T, Akagawa S, Kurashima A; NTM-BIORA (NTM infection in Biologic-treated RA patients) Study Investigators.

Mod Rheumatol. 2012 Sep;22(5):727-37. doi: 10.1007/s10165-011-0577-6. Epub 2011 Dec 30.

17.

Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands.

van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Thorax. 2009 Jun;64(6):502-6. doi: 10.1136/thx.2008.110957. Epub 2009 Feb 12.

PMID:
19213773
18.

Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study.

Ng B, Aslam F, Petersen NJ, Yu HJ, Suarez-Almazor ME.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1490-6. doi: 10.1002/acr.21736.

19.

Indolent infectious tenosynovitis afflicting rheumatoid patients treated with tumor necrosis factor inhibitors: case report.

Abrams R, Savoia M, Vinetz J, Dacus AR.

J Hand Surg Am. 2010 Jun;35(6):909-12. doi: 10.1016/j.jhsa.2010.01.027. Epub 2010 Mar 29.

PMID:
20350799
20.

Mycobacterial infections in human immuno-deficiency virus seropositive patients: role of non-tuberculous mycobacteria.

Khatter S, Singh UB, Arora J, Rana T, Seth P.

Indian J Tuberc. 2008 Jan;55(1):28-33.

PMID:
18361308
Items per page

Supplemental Content

Write to the Help Desk